CUREOMEX BIOPHARMA
Live / Registered — Registered (as of 10 Sept 2024)
What this means for you
Registered since 10 Sept 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98006888
- Registration number
- 7498829
- Mark type
- Stylized text
- Filed
- 22 May 2023
- Published for opposition
- 25 Jun 2024
- Registered
- 10 Sept 2024
- Attorney of record
- Michael K. Terkanian
Goods and services
- Class 042 — Scientific and technological services: Biotechnology research; Pharmaceutical research and development; Providing medical and scientific research information; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development of new products; Research and development in the pharmaceutical and biotechnology fields; Technical research in the field of pharmaceutical studies; Consulting services in the field of biotechnology; Consulting services in the field of pharmaceutical research and development; Providing information on the subject of scientific research in the field of biochemistry and biotechnology; Scientific research for medical purposes in the field of pharmaceuticals
Owner
- CureOmex BioPharma, LLC, Horsham, PA, US
- CureOmex BioPharma, LLC, Horsham, PA, US
- CureOmex BioPharma, LLC, Horsham, PA, US
Prosecution history
- 10 Sept 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 10 Sept 2024 — REGISTERED-PRINCIPAL REGISTER
- 25 Jun 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 25 Jun 2024 — PUBLISHED FOR OPPOSITION
- 05 Jun 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 22 May 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 21 May 2024 — RESTORE TO TEAS PLUS
- 21 May 2024 — REMOVED FROM TEAS PLUS
- 10 May 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 10 May 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 10 May 2024 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 21 Feb 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 21 Feb 2024 — NON-FINAL ACTION E-MAILED
- 21 Feb 2024 — NON-FINAL ACTION WRITTEN
- 14 Feb 2024 — ASSIGNED TO EXAMINER